Abstracts tagged "autoimmune diseases"

Abstract Number: 0504 • ACR Convergence 2025
Spatial profiling of gene signatures in synovial tissue informs treatment strategy for Rheumatoid Arthritis
Vincent Wong¹, Katie Lowe², Annabelle Small³, Christopher Altmann³, Susanna Proudman⁴, Malcolm Smith², Wittaya Suwakulsiri⁵, Ranjeny Thomas⁵, Chung Hoow Kok⁶ and Mihir Wechalekar⁷, ¹College of Medicine and Public Health, Bedford Park, South Australia, Australia, ²Flinders University, Adelaide, South Australia, Australia, ³Flinders University, Bedford Park, South Australia, Australia, ⁴The University of Adelaide, Adelaide, Victoria, Australia, ⁵Frazer Institute, University of Queensland, Brisbane, Queensland, Australia, ⁶Centre for Cancer Biology, and Clinical Health Sciences, University of South Australia, Adelaide, South Australia, Australia, ⁷Flinders Medical Centre and Flinders University, Bedford Park, South Australia, Australia
Background/Purpose: Rheumatoid arthritis (RA) shows heterogeneous therapeutic responses that may reflect diversity within synovial tissue (ST). We aimed to identify gene signatures that predict Adalimumab…
Abstract Number: 0287 • ACR Convergence 2025
Comprehensive Profiling of Neutrophil Subsets Reveals Functional Signatures Linked to Vasculopathic Features in Patients with Inflammatory Myopathies
Daniel Alberto Carrillo-Vázquez¹, Beatriz Alcalá-Carmona¹, Jennifer Tiaré Balderas Miranda², Yatzil Reyna Juárez³, María José Ostos Prado¹, Samuel Govea-Peláez¹, Nancy R Mejía Domínguez⁴, Guillermo Juárez Vega⁴, Karina Santana-De Anda¹, Jiram Torres-Ruiz⁵ and Diana Gómez-Martín⁶, ¹Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ²Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, ³Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico, ⁴Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ⁵INCMNSZ, Ciudad de México, Mexico, ⁶INCMNSZ, Mexico city, Federal District, Mexico
Background/Purpose: Vasculopathic manifestations of idiopathic inflammatory myopathies (IIM) such as interstitial lung disease (ILD), calcinosis, skin ulcers, mechanic’s hands, are characterized by immune-mediated vascular damage.…
Abstract Number: 0253 • ACR Convergence 2025
Ophthalmology Screening for Asymptomatic Uveitis in Sarcoidosis Patients: A Single-Center Investigation
Justin Nguyen¹, Philip Bucur², Sai Patel², Aamer Syed², Thomas Iden³, Jessica McLaughlin², Neha Gupta², Jordana Kron², Kelly Gwathmey², Ryan Canissario², Vaishali Patel² and Huzaefah Syed², ¹Virginia Commonwealth University Medial Center, Richmond, VA, ²Virginia Commonwealth University Medical Center, Richmond, VA, ³Virginia Commonwealth University Medical Center, Richmond
Background/Purpose: Asymptomatic ocular involvement must be considered in any patient with sarcoidosis. If left untreated, severe complications, including vision loss, can occur. As a result,…
Abstract Number: 0158 • ACR Convergence 2025
Association between newer COVID-19 vaccines and COVID-19 related hospitalizations among people with autoimmune rheumatic diseases in the U.S. National COVID Cohort Collaborative (N3C)
Lesley Jackson¹, jerrod anzalone², Rahima Begum³, Fazlur Rahman¹, Namrata Singh⁴, Londyn Robinson⁵, Kaleb Michaud², Kenneth Saag⁶, Jasvinder Singh⁷, Rena Patel¹ and Maria I. ("Maio") Danila⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Nebraska Medical Center, Omaha, NE, ³University of Alabama at Birmingham, Birmingham, ⁴University of Washington, Bellevue, WA, ⁵University of Washington, Seattle, WA, ⁶The University of Alabama at Birmingham, Birmingham, AL, ⁷Baylor College of Medicine, Houston, TX, ⁸University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: People with autoimmune rheumatic diseases (AIRD) are at higher risk for serious complications and poor outcomes from COVID-19 infection. Data is lacking on outcomes…
Abstract Number: 0031 • ACR Convergence 2025
Meta-Analysis of Trans-Disease Microbial Biomarkers of Protection and Pathogenesis in Autoimmune Conditions: Results from the AMP AIM Consortium
Kevin Bu¹, Rebecca Blank², Alba Boix-Amoros³, Adam Cantor⁴, Jose Scher⁵ and Jose Clemente¹, ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²NYU Langone Health, New York, NY, ³Icahn School of Medicine, New York, NY, ⁴Icahn School of Medicine, New York, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Autoimmune and immune-mediated diseases (AIMDs) affect over 20 million Americans. The sharp increase in prevalence of these disorders over recent decades suggests that factors…
Abstract Number: 0001 • ACR Convergence 2025
ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases
Gang Bian¹, Tengteng Li¹, Huiling Liu², Zaoshun Hu², Peng Chen¹, Jay Mei³ and Bing Hou³, ¹Shanghai Antengene Corporation Limited, Shanghai, China (People's Republic), ²Antengene (Hangzhou) Biologics, Hangzhou, Zhejiang, China (People's Republic), ³Antengene Corporation, Shanghai, China (People's Republic)
Background/Purpose: CD19-targeted therapies, such as chimeric antigen receptor (CAR)-T or T-cell engagers (TCE), have been approved for the treatment of B cell malignancies. By depleting…
Abstract Number: 2668 • ACR Convergence 2025
CD14⁺ Myeloid Cells Mediate UVB Photosensitivity in Autoimmune Skin Disease via a Spatially Resolved Inflammatory Circuit
Nazgol Haddadi¹, Khashayar Afshari¹, Yuqing Wang¹, Carolina S. Lopes¹, Chee-Huat L. Eng², Nuria Martinez-Gutierrez¹, Leah Whiteman¹, Kevin Wei³, Kirsten Frieda², Stefania Gallucci¹, Misha Rosenbach⁴, Ruth Ann Vleugels⁵, John E. Harris¹, Manuel Garber¹ and Mehdi Rashighi¹, ¹UMass Chan Medical School, Worcester, MA, ²Spatial Genomics, Inc., Pasadena, CA, ³Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Brigham and Women's Hospital, Chestnut Hill, MA
Background/Purpose: Inflammatory skin diseases vary widely in symptoms and causes. While ultraviolet (UV) light helps treat some like vitiligo and psoriasis, in conditions like cutaneous…
Abstract Number: 2563 • ACR Convergence 2025
Factors Associated With Medication Use in the Preconception and Perinatal Period Among Women With Autoimmune Disorders: A Systematic Review
Olivia Novosel¹, Sabrina Chiodo¹, Yanara Marks¹, Lux Li¹, Renee Gabrielle Fajardo¹, Lauren Tailor¹, Lucy Zhao¹, Jessie Cunningham², Cristina Longo³ and Sonia Grandi¹, ¹Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, Toronto, ON, Canada, ²Health Sciences Library, The Hospital for Sick Children, Toronto, ON, Canada, Toronto, ON, Canada, ³Faculty of Pharmacy, University of Montreal, Montréal, QC, Canada, Montreal, ON, Canada
Background/Purpose: Autoimmune disorders (AD) disproportionately affect women of reproductive age, presenting challenges for disease management during the preconception and perinatal periods. Treatment decisions are complicated…
Abstract Number: 2440 • ACR Convergence 2025
Effect of Cenerimod on Four Main Clinical Items of SLEDAI-2K Score in SLE Patients in a Phase 2b Study
Anca Askanase¹, Bruno Flamion², Ouali Berkani² and Cecile Dubois², ¹Columbia University Medical Center, New York, NY, ²Viatris Innovation, Allschwil, Switzerland
Background/Purpose: Cenerimod is a selective S1P1 receptor modulator that has the potential to reduce the abnormal immune response seen in Systemic lupus erythematosus (SLE) thereby…
Abstract Number: 2220 • ACR Convergence 2025
Human Milk Fatty Acid Profiles Among Breastfeeding Mothers With and Without Systemic Autoimmune Rheumatic Diseases
Rashmi Dhital¹, Kerri Bertrand², Dilli Poudel³, Christina Chambers⁴ and Monica Guma², ¹Vanderbilt University Medical Center, Brentwood, TN, ²University of California San Diego, San Diego, CA, ³Vanderbilt University Medical Center, Nashville, TN, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs) such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are characterized by chronic systemic inflammation and often require…
Abstract Number: 1888 • ACR Convergence 2025
Developing Machine Learning Algorithm in Electronic Health Record to Accurately Identify Psoriasis Patients
Dilli Poudel¹, Leslie Crofford², Avery Fortier³, Lee Wheless⁴, Georgina Sellyn⁴, Gyaljin Sherpa⁵, Alexis Ogdie⁶ and Paras Karmacharya⁷, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Melbourne, AR, ³Vanderbilt University, Lexington, MA, ⁴Vanderbilt University, Nashville, TN, ⁵Mercy Health - St. Elizabeth Youngstown Hospital, Newyork, NY, ⁶Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ⁷Vanderbilt University, Nashville, TN, Hermitage, TN
Background/Purpose: Accurate identification of patients with psoriasis from large electronic health record (EHR) databases is crucial for conducting robust real-world research. While EHRs offer an…
Abstract Number: 1732 • ACR Convergence 2025
Incidence of Flares in Pre-existing Rheumatologic Diseases Among Patients with Solid Tumors Undergoing Cancer Immunotherapy: A Systematic Review and Meta-analysis
Takemichi Matsui¹, Kenji Yamada², Toshiaki Takahashi³, Yoshito Nishimura⁴ and Yu Fujiwara⁵, ¹Department of Medicine, Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ²Department of Allergy and Rheumatology, Kameda Medical Center, Chiba, Japan, ³Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, ⁴Division of Hematology/Oncology, Mayo Clinic, Rochester, MN, ⁵Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Background/Purpose: Immune checkpoint inhibitors (ICIs) have become essential in cancer treatment, offering significant survival benefits across various malignancies. However, ICIs can cause immune-related Adverse Events…
Abstract Number: 1563 • ACR Convergence 2025
RESET-SSc: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Systemic Sclerosis
Dinesh Khanna¹, Monalisa Ghosh¹, Ankoor Shah², Sonali Bracken³, george georges⁴, Carrie Richardson⁵, Pei-Suen Tsou¹, Charles Ross⁶, Carleigh Zahn¹, Courtney Little⁷, Carl diCasoli⁷, Mikaela Raymond⁷, Adreeja GuhaRay⁷, Jenell Volkov⁷, Daniel Nunez⁷, Thomas Furmanak⁷, Jason Stadanlick⁷, Larissa Ishikawa⁷, Zachary Vorndran⁷, Alexandra Ellis⁷, Jazmean Williams⁷, Steve Flanagan⁷, Quynh Lam⁸, Domenick Braccia⁸, Fatemeh Hadi-Nezhad⁸, Raj Tummala⁸, Samik Basu⁷ and David Chang⁹, ¹University of Michigan, Ann Arbor, MI, ²Duke University, Durham, NC, ³Duke University Medical Center, Durham, NC, USA, Apex, NC, ⁴Northwestern Medicine, Evanston, IL, ⁵Northwestern University, Chicago, IL, ⁶University of Michigan, Ann Arbor, ⁷Cabaletta Bio, Philadelphia, PA, ⁸Cabaletta Bio, Philadelphia, ⁹Cabaletta Bio, Bryn Mawr, PA
Background/Purpose: The treatment goals for systemic sclerosis (SSc) are to control disease activity, limit progression of organ damage and decrease long-term morbidity and mortality. Therapies…
Abstract Number: 1474 • ACR Convergence 2025
Rethinking Heart Risk Prediction for Lupus Patients
Aretha On¹, Xiwei Yang¹, Shae Chambers², Hammad Ali³, Touraj Khosravi-Hafshejani³, Lais Lopes Almeida Gomes², Rui Feng⁴, Kevin Jon Williams⁵ and Victoria Werth⁶, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, U.S./Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, U.S., Philadelphia, PA, ⁴Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA, ⁵Department of Cardiovascular Sciences, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA, Philadelphia, PA, ⁶University of Pennsylvania, Wynnewood, PA
Background/Purpose: Patients with lupus erythematosus (LE) are at an increased risk of clinical events from atherosclerotic cardiovascular disease (ASCVD), yet the accuracy of risk estimation…
Abstract Number: 1282 • ACR Convergence 2025
Real-world use of belimumab in childhood-onset SLE in Spain: cross-sectional analysis from a multicenter study (JULES registry)
Alina-Lucica Boteanu¹, Clara Udaondo², Joan Calzada³, Daniel Clemente Garulo⁴, Juan Carlos Nieto Gonzáles⁵, Eugenia Enriquez⁶, inmaculada Calvo Penades⁷, Lourdes Villalobos⁸, Belen Sevilla⁹, Sara Murias¹⁰, Berta Magallares¹¹, Ana Capilla¹², Jaime Arroyo¹³, Beatriz Bravo¹⁴, Gisela Diez-Cordoves¹⁵, Marisol Camacho¹⁶, Genaro grana¹⁷, Juan Jose Bethencourt¹⁸, Pablo Mesa¹⁹, Natalia Palmou²⁰, Mireia Lopez Corbeto²¹, Judith Sanchez²², Maria Isabel Gonzalez²³, isabel Patora Granados bautista²⁴, Clara Moriano²⁵, Diego Dios¹⁷, Lorena Exposito²⁶, Alicia Garcia²⁷, Laura Martin²⁸, David Fernandez²⁹, Laura Trujillo¹⁴, Anahy Maria Brandy³⁰ and CARLOS GUILLEN-ASTETE³¹, ¹H.U. Ramón y Cajal, Madrid, Spain, ²La Paz University Hospital, Madrid, Spain, ³University Hospital Sant Joan de Deu, Barcelona, Spain, ⁴H.U Niño Jesús, Madrid, Spain, ⁵H.U Gregorio Marañón, Madrid, Spain, ⁶Clínica Universidad de Navarra, Madrid, Spain, ⁷Pediatric Rheumatology Department. HUP La Fe, Valencia, Spain, ⁸Ramon y Cajal Hospital, MADRID, Spain, ⁹Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ¹⁰H.U Central de Asturias, Oviedo, Spain, ¹¹Hospital de Sant Pau, Bareclona, ¹²H.U de La Merced, Sevilla, Spain, ¹³HOSPITAL UNIVERSITARIO LA PAZ, MADRID, ¹⁴H.U Virgen de Las Nieves, Granada, Spain, ¹⁵H. R. U. Malaga, Malaga, Spain, ¹⁶H.U. Virgen del Rocío, Sevilla, Spain, ¹⁷H.U de A Coruña, A Coruña, Spain, ¹⁸H.U. Canarias, Canarias, Spain, ¹⁹H.U Virgen de la Arrixaca, Murcia, Spain, ²⁰H.U. marques de Valdecilla, Santander, Spain, ²¹H.U Vall d´Hebron, Barcelona, Spain, ²²Pediatric Rheumatology Department, Taulí Hospital Universitari-Institut d'Investigació i Innovació Parc Taulí (I³PT-CERCA), Sabadell (Spain)., Sabadell, Spain, ²³H.U. La Fé, Valencia, Spain, ²⁴H.U Toledo, Toledo, Spain, ²⁵Hospital León, LEON, Castilla y Leon, Spain, ²⁶H.U Canarias, Canarias, Spain, ²⁷Rheumatologist, La Laguna, Spain, ²⁸H.R.U Malaga, Malaga, Spain, ²⁹Complejo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ³⁰Hospital Germans Trias i Pujol, Badalona, Spain, ³¹H.U Ramón y Cajal, Madrid, Spain
Background/Purpose: SLE is a multisystemic autoimmune disease with several manifestations. Childhood-onset SLE (cSLE) has a more severe disease course than adult-onset SLE, with a higher…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].